Pozycja flutykazonu z salmeterolem w terapii astmy w świetle nowych wytycznych GINA 2019 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2019
Słowa kluczowe:
salmeterol, flutykazon, GINA, astma
##plugins.themes.bootstrap3.article.main##
Abstrakt
Kombinację salmeterol + flutykazon z jednego inhalatora stosuje się w leczeniu astmy od ponad 20 lat. Od tego też czasu zajmuje ona zasadnicze miejsce w wytycznych. Również w GINA 2019 kombinacja ta znajduje się w grupie leków pierwszego wyboru w leczeniu astmy stopnia 3.–5. Z badań klinicznych wynika, że postępowanie to jest skuteczne i bezpieczne, znacząco zwiększa liczbę dni bez objawów astmy i bez leków doraźnych oraz zapewnia likwidację nadreaktywności oskrzeli.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pawliczak, R. (2019). Pozycja flutykazonu z salmeterolem w terapii astmy w świetle nowych wytycznych GINA 2019 . Medycyna Faktów , 12(3(44), 243-245. https://doi.org/10.24292/01.MF.0319.9
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate. Pharmacoeconomics 1999; 16(supl. 2): i-viii, 1-34.
2. Aubier M., Pieters W.R., Schlösser N.J., Steinmetz K.O.: Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir. Med. 1999; 93(12): 876-884.
3. Chapman K.R., Ringdal N., Backer V. et al.: Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6(1): 45-51.
4. Condemi J.J., Goldstein S., Kalberg C. et al.: The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann. Allergy Asthma Immunol. 1999; 82(4): 383-389.
5. Spencer C.M., Jarvis B.: Salmeterol/fluticasone propionate combination. Drugs 1999; 57(6): 933-940; discussion 941-943.
6. van Noord J.A., Schreurs A., Mol S., Mulder P.: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54(3): 207-212.
7. Bateman E.D., Bousquet J., Busse W.W. et al.: Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008; 63(7): 932-938.
8. Lundback B., Rönmark E., Lindberg A. et al.: Asthma control over 3 years in a real-life study. Respir. Med. 2009; 103(3): 348-355.
9. Trautmann M., Banik N., Tews J.T., Jorres R.A.: Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a „real-life” setting. Eur. J. Med. Res. 2007; 12(6): 255-263.
10. Woodcock A.A., Bagdonas A., Boonsawat W. et al.: Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim. Care Respir. J. 2007; 16(3): 155-161.
11. Bateman E.D., Clark T.J., Frith L. et al.: Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study. J. Asthma 2007; 44(8): 667-673.
12. Bateman E.D., Bousquet J., Keech M.L. et al.: The correlation between asthma control and health status: the GOAL study. Eur. Respir. J. 2007; 29(1): 56-62.
13. Briggs A.H., Bousquet J., Wallace M.V. et al.: Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006; 61(5): 531-536.
14. Stoloff S.W., Stempel D.A., Meyer J. et al.: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 2004; 113(2): 245-251.
2. Aubier M., Pieters W.R., Schlösser N.J., Steinmetz K.O.: Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir. Med. 1999; 93(12): 876-884.
3. Chapman K.R., Ringdal N., Backer V. et al.: Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6(1): 45-51.
4. Condemi J.J., Goldstein S., Kalberg C. et al.: The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann. Allergy Asthma Immunol. 1999; 82(4): 383-389.
5. Spencer C.M., Jarvis B.: Salmeterol/fluticasone propionate combination. Drugs 1999; 57(6): 933-940; discussion 941-943.
6. van Noord J.A., Schreurs A., Mol S., Mulder P.: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54(3): 207-212.
7. Bateman E.D., Bousquet J., Busse W.W. et al.: Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008; 63(7): 932-938.
8. Lundback B., Rönmark E., Lindberg A. et al.: Asthma control over 3 years in a real-life study. Respir. Med. 2009; 103(3): 348-355.
9. Trautmann M., Banik N., Tews J.T., Jorres R.A.: Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a „real-life” setting. Eur. J. Med. Res. 2007; 12(6): 255-263.
10. Woodcock A.A., Bagdonas A., Boonsawat W. et al.: Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim. Care Respir. J. 2007; 16(3): 155-161.
11. Bateman E.D., Clark T.J., Frith L. et al.: Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study. J. Asthma 2007; 44(8): 667-673.
12. Bateman E.D., Bousquet J., Keech M.L. et al.: The correlation between asthma control and health status: the GOAL study. Eur. Respir. J. 2007; 29(1): 56-62.
13. Briggs A.H., Bousquet J., Wallace M.V. et al.: Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006; 61(5): 531-536.
14. Stoloff S.W., Stempel D.A., Meyer J. et al.: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 2004; 113(2): 245-251.